Long intergenic non-protein coding RNA 2562 (LINC02562)

Long intergenic non-protein coding RNA 2562 (LINC02562) is a non-protein-coding transcript classified as a long intergenic non-coding RNA (lincRNA), meaning it is longer than 200 nucleotides and transcribed from regions that do not overlap any known protein-coding genes[2][3]. LINC02562 is overexpressed in human lung adenocarcinoma and lung squamous cell carcinoma tissues and is implicated in lung cancer development. Mechanistically, LINC02562 competes with the protein YBX1 for binding to the DNA repair protein NTHL1, modulating DNA damage repair mechanisms and promoting tumor progression, making it a candidate as a potential therapeutic target in lung cancer[2]. More broadly, lincRNAs regulate gene expression at various levels by interacting with chromatin, proteins, and RNA, and play context-dependent roles in cell biology and disease[3]. LINC02562's emerging role specifically ties it to cancer pathogenesis via DNA repair modulation. There are no direct therapeutic agents targeting LINC02562 as of September 2025, nor is it yet established in clinical biomarker panels or associated with unique safety or toxicity concerns in a therapeutic context.

Other names

LINC02562RP11-44F21.5

Not applicable; LINC02562 acts as a molecular decoy and modulator, particularly in the NTHL1/YBX1 axis for DNA repair